Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 16583385)

1.

Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis.

Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, Bathon JM.

Arthritis Rheum. 2006 Apr 15;55(2):333-7. No abstract available.

2.

Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.

Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG.

Arthritis Rheum. 2007 Apr;56(4):1125-33.

3.

Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers.

Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, Dougados M.

Clin Exp Rheumatol. 2007 May-Jun;25(3):430-6.

PMID:
17631740
4.

Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.

den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, de Waal-Malefijt M, van den Hoogen FH.

J Rheumatol. 2007 Apr;34(4):689-95.

PMID:
17117492
5.
6.

Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.

Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH.

Arthritis Rheum. 2007 Jun;56(6):1754-64.

7.

Nonserious infections: should there be cause for serious concerns?

Dao KH, Herbert M, Habal N, Cush JJ.

Rheum Dis Clin North Am. 2012 Nov;38(4):707-25. doi: 10.1016/j.rdc.2012.08.016. Review.

PMID:
23137578
8.

Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.

Asahina A, Ishii N, Tohma S.

J Dermatol. 2012 Feb;39(2):199-201. doi: 10.1111/j.1346-8138.2011.01243.x. Epub 2011 Apr 5. No abstract available.

PMID:
21463364
9.

Tumour necrosis factor inhibitors--what we need to know.

Hasan U.

N Z Med J. 2006 Dec 1;119(1246):U2336. Review.

PMID:
17151710
10.

Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.

van der Stoep D, Braunstahl GJ, van Zeben J, Wouters J.

J Rheumatol. 2009 Dec;36(12):2847-8. doi: 10.3899/jrheum.090307. No abstract available.

PMID:
19966199
11.

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.

Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group.

J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15.

PMID:
21498482
12.

Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?

Gabriel SE.

Arthritis Rheum. 2008 Mar;58(3):637-40. doi: 10.1002/art.23280. No abstract available.

13.

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.

Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A, Gremese E, Iannone F, Sebastiani M, Ziglioli T, Biasi D, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Gorla R, Govoni M, Lapadula G, Marchesoni A, Salaffi F, Punzi L, Triolo G, Ferraccioli G.

Autoimmun Rev. 2012 Dec;12(2):225-9. doi: 10.1016/j.autrev.2012.06.008. Epub 2012 Jul 13.

PMID:
22796281
14.

Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis.

Boulton JG, Bourne JT.

Rheumatology (Oxford). 2007 Jan;46(1):178-9. Epub 2006 Sep 23. No abstract available.

15.

Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.

Hyrich KL, Silman AJ.

J Rheumatol. 2006 May;33(5):831-3. No abstract available.

16.

[TNF inhibitors for treatment of rheumatoid arthritis].

Otomo K, Koike T.

Nihon Naika Gakkai Zasshi. 2008 Oct 10;97(10):2405-12. Review. Japanese. No abstract available.

PMID:
19149036
17.

Coxiella burnetii infection (Q fever) in rheumatoid arthritis patients with and without anti-TNFα therapy.

Schoffelen T, Kampschreur LM, van Roeden SE, Wever PC, den Broeder AA, Nabuurs-Franssen MH, Sprong T, Joosten LA, van Riel PL, Oosterheert JJ, van Deuren M, Creemers MC.

Ann Rheum Dis. 2014 Jul;73(7):1436-8. doi: 10.1136/annrheumdis-2014-205455. Epub 2014 May 2. No abstract available.

PMID:
24794150
18.

[Should we be afraid of the anti-TNFalpha drugs in 2008?].

Gaudin P.

Rev Med Interne. 2008 Dec;29(12):971-4. doi: 10.1016/j.revmed.2008.04.022. Epub 2008 Jun 20. French. No abstract available.

PMID:
18571291
19.

Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Hyrich KL, Silman AJ, Watson KD, Symmons DP.

Ann Rheum Dis. 2004 Dec;63(12):1538-43. Epub 2004 Jul 8. Review.

20.

[Adverse effects of biologic agents in treatment of rheumatoid arthritis--prevention of tuberculosis].

Tomono K, Hashimoto S.

Nihon Rinsho. 2005 Jan;63 Suppl 1:573-8. Review. Japanese. No abstract available.

PMID:
15799420
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk